Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Six-month, Open-label, Multi-center Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents With ADHD

Next Previous
Search
Trial Profile

A Six-month, Open-label, Multi-center Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents With ADHD

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Registrational
  • Sponsors Rhodes Pharmaceuticals

    • Most Recent Events

    • 01 Nov 2021 Results published in the Journal of Child and Adolescent Psychopharmacology
    • 14 Jun 2021 Results presented in the Adlon Therapeutics Media Release.
    • 31 May 2021 Results of post-hoc analyses based on a randomized, double-blind, forced-dose, placebo-controlled trial (NCT02139124) and an open-label extension study (NCT02168127) of the efficacy and safety of the extended-release methylphenidate hydrochloride formulation PRC-063 in adults with ADHD published in the CNS Drugs

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top